JPRN-UMIN000012056招募中未知
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations - Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 75years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) EGFR mutation T790M positive 2) Active concomitant malignancy. 3) Interstitial pneumonia or pulmonary fibrosis on chest CT scans 4) Active concomitant malignancy 5) Pregnant or breast-feeding females 6) Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
不适用
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer without epidermal growth factor receptor mutations: A phase 2 trial.JPRN-UMIN000010526Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine42
已完成
不适用
Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations: A phase 2 study.non-small-cell lung cancerJPRN-UMIN000010525Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine30
已完成
2 期
A phase II study of Erlotinib for elderly patients previously treated non-small cell lung cancer without epidermal growth factor receptor mutationon-small cell lung cancerJPRN-UMIN000004561Fukushima Medical University, cancer center44
已完成
2 期
Phase II study of erlotinib monotherapy for elderly patients with untreated advanced non-small cell lung cancer, 75 years-old or older, and positive EGFR mutation status (OSAKA-LCSG1303)non-small cell lung cancerJPRN-UMIN000011472OSAKA-LCSG31
已完成
2 期
PhaseII trial of erlotinib for elderly patients with advanced or recurrent non-small cell lung cancerJPRN-UMIN000001873Keio University School of Medicine Division of Pulmonary Medicine40